ReviewCurrent treatment options in rheumatology2018
Current Treatment for Myositis.
Review in Current treatment options in rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Genetic Architecture of Idiopathic Inflammatory Myopathies From Meta-Analyses.Arthritis & rheumatology (Hoboken, N.J.) · 2025Pooled it
- Trial
- Investigating the Role of Type I Interferon Signaling on Muscle Disease Using Mouse Models.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- International IVIg prescription patterns in idiopathic inflammatory myopathies: real-world insights from the MyoNet survey.EULAR rheumatology open · 2026Article
- Article
- Development of siRNAs targeting interferon beta as a novel therapeutic approach for adult and juvenile dermatomyositis.Frontiers in immunology · 2026Article
- Inhibition of NOX4 attenuates muscle damage and mitochondrial dysfunction in inflammatory myopathy.Arthritis research & therapy · 2025Article
- Treatment guidelines for idiopathic inflammatory myopathies in adults: a comparative review.Rheumatology (Oxford, England) · 2025Review
- Review
- Single-cell profiling of muscle-infiltrating T cells in idiopathic inflammatory myopathies.EMBO molecular medicine · 2023Article
- Stromal vascular fraction in the treatment of myositis.Cell death discovery · 2023Review
- Article
- B-cell receptor profiling before and after IVIG monotherapy in newly diagnosed idiopathic inflammatory myopathies.Rheumatology (Oxford, England) · 2023Article
- A Narrative Review of Acthar Gel for the Treatment of Myositis.Rheumatology and therapy · 2023Review
- Clinical spectrum and outcomes of idiopathic inflammatory myopathies in South Africans.Frontiers in medicine · 2023Article
- Harnessing the benefits of yoga for myositis, muscle dystrophies, and other musculoskeletal disorders.Clinical rheumatology · 2022Review
- Inclusion Body Myositis and Neoplasia: A Narrative Review.International journal of molecular sciences · 2022Review
- Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Mortality Risk Stratification Using Cluster Analysis in Patients With Myositis-Associated Interstitial Lung Disease Receiving Initial Triple-Combination Therapy.Frontiers in medicine · 2022Article
- A severe case of non-infective myositis six weeks post intramuscular injections of Onabotulinum toxin A (Botox) in a young man with tetraplegia: case report.Spinal cord series and cases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe purpose of this review was to give an update on treatment modalities for patients with idiopathic inflammatory myopathies, or shortly myositis, excluding the subgroup inclusion body myositis, based on a literature survey on therapies used in myositis. Few controlled trials have been performed in patients with myositis; therefore, we also included a summary of open-label trials, case series, and case reports. RECENT
findingsGlucocorticoid (GC) in high doses is still the first-line treatment of patients with myositis. There is a general recommendation to combine GCs with another immunosuppressive agent in the early phase of disease to better control disease activity and possibly to reduce the risk for GC-related side effects. Furthermore, combining pharmacological treatment with individualized and supervised exercise can be recommended based on evidence. There is some evidence for the effect of rituximab in patients with certain myositis-specific autoantibodies, whereas other biologic agents are currently being tested in clinical trials. SUMMARY: Immunosuppressive treatment in combination with exercise is recommended for patients with myositis to reduce disease activity and improve muscle performance. Subgrouping of patients into clinical and serological subtypes may be a way to identify biomarkers for response to specific immunosuppressive and biological agents and should be considered in future trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.